<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Strongyloidiasis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Strongyloidiasis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Strongyloidiasis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karin Leder, MBBS, FRACP, PhD, MPH, DTMH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter F Weller, MD, MACP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Edward T Ryan, MD, DTMH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 01, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Strongyloidiasis is caused by infection with the soil-transmitted helminth <em>Strongyloides stercoralis</em>.</p><p>This organism is capable of completing its life cycle entirely within the human host, in contrast with all other soil-transmitted helminths that cannot replicate within hosts and require exogenous reinfections to sustain their life cycle.</p><p>As a consequence, infectious-stage larvae develop in the gastrointestinal tract and endogenously propagate ongoing infection. Therefore, chronic asymptomatic infection can be sustained for decades, and clinical manifestations can occur long after the initial infection. In addition, among patients with subclinical infections who subsequently become immunosuppressed, larval reproduction can lead to disseminated infection. (See  <a class="medical medical_review" href="/z/d/html/1398.html" rel="external">"Evaluation for infection before solid organ transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/1399.html" rel="external">"Evaluation for infection before hematopoietic cell transplantation"</a>.)</p><p>Issues related to other soil-transmitted helminths are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5673.html" rel="external">"Ascariasis"</a> and  <a class="medical medical_review" href="/z/d/html/5692.html" rel="external">"Enterobiasis (pinworm) and trichuriasis (whipworm)"</a> and  <a class="medical medical_review" href="/z/d/html/5721.html" rel="external">"Hookworm infection"</a>.)</p><p>Issues related to mass drug administration for control of parasitic infections are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/91857.html" rel="external">"Mass drug administration for control of parasitic infections"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H1334269417"><span class="h2">Geography</span><span class="headingEndMark"> — </span>Strongyloidiasis occurs in areas with poor sanitation. Strongyloidiasis is endemic in areas of tropical and subtropical regions; in these areas, the overall regional prevalence may exceed 30 percent [<a href="#rid1">1</a>], and some countries (such as Peru, Kenya, Namibia, and Papua New Guinea) have prevalence &gt;70 percent [<a href="#rid2">2</a>]. The global prevalence may be as high as 600 million cases [<a href="#rid3">3</a>]. Southeast Asia, Africa, and Western Pacific Regions account for approximately three-quarters of all infections globally [<a href="#rid3">3</a>]. Human infections with <em>S. stercoralis</em> occur in Australia and temperate areas such as North America, Europe, Japan, and Australia [<a href="#rid4">4-11</a>].</p><p>In the United States, infections occur among residents of the southeastern states and Appalachian regions [<a href="#rid12">12,13</a>] where <em>S. stercoralis </em>larvae may be present in soil in regions with poor sanitation [<a href="#rid14">14</a>]. In one report of United States hospitalizations for strongyloidiasis between 2003 and 2018, strongyloidiasis was more prevalent in the northeastern United States including the mid-Atlantic region [<a href="#rid15">15</a>]. Infections also occur among individuals who have resided in endemic areas (including internal migrations, immigrants, refugees, travelers, and military personnel) [<a href="#rid16">16-18</a>].</p><p>In a review and meta-analysis describing the prevalence of strongyloidiasis among migrants from endemic areas, the seroprevalence of strongyloidiasis was 12 percent; the prevalence was highest among migrants from East Asia and the Pacific (17 percent), followed by those from sub-Saharan Africa (14 percent) and Latin America/the Caribbean (11 percent) [<a href="#rid19">19</a>]. Another meta-analysis including migrants to Spain from sub-Saharan Africa, Latin America, and North Africa noted seroprevalence of <em>S. stercoralis</em> infection to be 20, 14, and 8 percent, respectively [<a href="#rid20">20</a>].</p><p>Canine infections with <em>S. stercoralis </em>are being recognized in Europe and elsewhere [<a href="#rid21">21</a>], but the zoonotic relevance of canine infections to human infections remains to be ascertained [<a href="#rid22">22</a>]. A related species, <em>Strongyloides fuelleborni</em>, also a soil-transmitted infection that infects non-human primates (including monkeys), has uncommonly infected humans living in proximity to monkeys [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H2598039156"><span class="h2">Transmission</span><span class="headingEndMark"> — </span>The most common mode for transmission of strongyloidiasis is via skin contact with contaminated soil. Lack of adequate sanitation facilities is an important risk factor [<a href="#rid4">4</a>]. In endemic areas, infection may be prevented by wearing shoes to avoid contact of bare feet with infected soil. </p><p>Less common modes of transmission include fecal-oral transmission and person-to-person transmission (via contact with fecally contaminated, larvae-bearing fomites or via sexual contacts [<a href="#rid24">24</a>]). Nosocomial transmission of strongyloidiasis has been described; standard precautions are sufficient for prevention [<a href="#rid13">13,25,26</a>]. </p><p>Transplant recipients receiving organs or tissues from donors with epidemiologic risk for asymptomatic <em>Strongyloides</em> infection are at risk for donor-derived strongyloidiasis [<a href="#rid27">27,28</a>]. In addition, immunosuppressed individuals are at risk for developing <em>Strongyloides</em> hyperinfection/disseminated disease; this can occur as a consequence of accelerated autoinfection even in the setting of a remote history of initial infection. (See <a class="local">'Severe manifestations'</a> below.)</p><p>Issues related to prevention of infection among immunosuppressed individuals are discussed below. (See <a class="local">'Asymptomatic individuals'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h2">Life cycle and autoinfection</span><span class="headingEndMark"> — </span>The life cycle begins when human skin contacts filariform larvae (the infective larval stage) of <em>S. stercoralis</em>, which are found in soil or other materials contaminated with human stool (<a class="graphic graphic_figure graphicRef87284" href="/z/d/graphic/87284.html" rel="external">figure 1</a>). The filariform larvae penetrate the skin and migrate via the bloodstream and lymphatics to the lungs, where they penetrate into the alveolar air sacs. The larvae then ascend the tracheobronchial tree and are swallowed.</p><p>The larvae mature into adult worms that burrow into the mucosa of the duodenum and jejunum. Adult worms may live for up to five years. In the apparent absence of male adults, pathogenic adult females produce eggs, from which early larvae and then noninfectious larvae (rhabditiform larvae) develop within the lumen of the gastrointestinal (GI) tract. The rhabditiform larvae (<a class="graphic graphic_picture graphicRef63898" href="/z/d/graphic/63898.html" rel="external">picture 1</a>) are generally passed in the stool. The duration of the cycle from dermal penetration of filariform larvae to appearance of rhabditiform larvae in the stool is approximately three to four weeks.</p><p>In addition, autoinfection can occur; in this part of the life cycle, the rhabditiform larvae become infective filariform larvae within the human GI tract (<a class="graphic graphic_figure graphicRef87284" href="/z/d/graphic/87284.html" rel="external">figure 1</a>). The filariform larvae can then penetrate the intestinal mucosa (internal autoinfection) or the perianal skin (external autoinfection) to complete the life cycle by migrating via the bloodstream and lymphatics to the lungs and then the intestine. Transformation of rhabditiform larvae to filariform larvae within the GI tract may be accelerated by constipation, diverticula, other conditions that reduce bowel motility, and use of steroids or other immunosuppressive agents. Via autoinfection, the burden of adult worms in infected humans can increase substantially in the absence of ongoing epidemiologic re-exposures. </p><p>In general, autoinfection is limited by an intact immune response; however, ongoing low levels of autoinfection may permit the infection to persist for decades and cause clinical manifestations to occur long after the initial infection [<a href="#rid29">29</a>]. Delayed onset of symptomatic infection has been observed among World War II ex-prisoners of war who worked on the Burma-Thailand railroad and presented with clinical manifestations more than 40 years after initial exposure [<a href="#rid30">30</a>]. </p><p>In patients with glucocorticoid administration and/or diminished cell-mediated immunity, hyperinfection with disseminated disease may develop as a consequence of autoinfection [<a href="#rid31">31,32</a>]. (See <a class="local">'Severe manifestations'</a> below.)</p><p>Besides <em>S. stercoralis</em>, the only helminthic parasite capable of completing its life cycle entirely within the human host is <em>Capillaria philippinensis</em>. (See  <a class="medical medical_review" href="/z/d/html/5694.html" rel="external">"Miscellaneous nematodes", section on 'Capillariasis'</a>.) </p><p class="headingAnchor" id="H612482635"><span class="h2">Risk factors for severe disease</span><span class="headingEndMark"> — </span>Immunosuppressed individuals are at risk for developing <em>Strongyloides</em> hyperinfection/disseminated disease; this can occur as a consequence of accelerated autoinfection even in the setting of a remote history of initial infection. </p><p>Risk factors include:</p><p class="bulletIndent1"><span class="glyph">●</span>Conditions associated with impairment of cell-mediated immunity, including [<a href="#rid31">31</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Human T-lymphotropic virus type I (HTLV-I) infection – HTLV-I infection is an important risk factor for disseminated strongyloidiasis. One review and meta-analysis found that in regions of co-endemicity, those infected with HTLV-1 were more likely to be coinfected with <em>S. stercoralis</em> and, if coinfected, were more likely to fail treatment and develop severe manifestations of infection [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/8317.html" rel="external">"Human T-lymphotropic virus type I: Disease associations, diagnosis, and treatment"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) – Disseminated strongyloidiasis can occur in patients with AIDS [<a href="#rid34">34,35</a>], but it occurs less frequently than in patients with HTLV-I and is much less common than might be predicted given the co-endemicity of the two infections [<a href="#rid36">36</a>]. In one systematic review including 7 studies and more than 2000 patients hospitalized with HTLV-I and strongyloidiasis, HIV infection was found in 41 percent of cases [<a href="#rid33">33</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Malignancy</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypogammaglobulinemia (including nephrotic syndrome and multiple myeloma) [<a href="#rid37">37,38</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Congenital immunodeficiency</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Alcoholism and/or malnutrition</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medical interventions associated with immunosuppression:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Administration of corticosteroids, cytotoxic drugs, or tumor necrosis factor inhibitors [<a href="#rid31">31,39-49</a>]. Hyperinfection syndrome has been described regardless of dose, duration, or route of corticosteroid administration; even short courses (eg, 6 to 17 days) have been associated with hyperinfection [<a href="#rid4">4,42</a>]. Hyperinfection has developed in patients with COVID-19-treated corticosteroids [<a href="#rid50">50,51</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Solid organ transplantation, either from an infected donor to an uninfected recipient, or from an uninfected donor to an infected recipient whose subclinical infection is unmasked by immunosuppression [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hematopoietic stem cell transplantation [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy – Data on the risk of severe strongyloidiasis during pregnancy are limited; disseminated disease in pregnant patients has been described [<a href="#rid52">52</a>]. In one case, fatal disseminated strongyloidiasis developed in a patient who was infected with HTLV-1 and had received corticosteroids [<a href="#rid52">52,53</a>].</p><p></p><p>Issues related to prevention of <em>Strongyloides</em> infection prior to initiation of immunosuppressive therapy are discussed below. (See <a class="local">'Asymptomatic individuals'</a> below.)</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H4080453714"><span class="h2">Signs and symptoms</span><span class="headingEndMark"> — </span>Due to the capacity for internal reinfection, infection due to <em>S. stercoralis</em> may persist for decades. Clinical manifestations may be present in the context of chronic infection; moreover, infected individuals are at risk for severe manifestations.</p><p class="headingAnchor" id="H36716578"><span class="h3">Acute infection</span><span class="headingEndMark"> — </span>The clinical manifestations of acute strongyloidiasis reflect the path of larval migration from the site of skin penetration to the small intestine, where new adults will develop and start producing larvae (<a class="graphic graphic_figure graphicRef87284" href="/z/d/graphic/87284.html" rel="external">figure 1</a>) [<a href="#rid4">4</a>]. Clinical manifestations during larval penetrations are rarely recognized and reported. </p><p>Infected individuals may experience immediate irritation at the site of skin penetration [<a href="#rid54">54</a>]. Within a week following transmission, a dry cough may develop. Following the establishment of infection in the small intestine (as early as the third week following transmission), gastrointestinal (GI) symptoms such as diarrhea, constipation, abdominal pain, or anorexia may occur. </p><p>Approximately one month following transmission, larval production by the newly established adult worms begins; new cycles of infection may be initiated via autoinfection (either within the intestinal mucosa or the perianal skin).</p><p class="headingAnchor" id="H835275650"><span class="h3">Chronic infection</span><span class="headingEndMark"> — </span>When present, clinical symptoms usually involve the GI tract and/or the skin; respiratory symptoms occur less commonly:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal symptoms</strong> – When present, GI symptoms are usually mild. Abdominal pain may be periumbilical or mid-epigastric [<a href="#rid55">55</a>], the latter likely due to the duodenal localization of adult and larval parasites. Other symptoms may include diarrhea, constipation, intermittent vomiting, and borborygmi. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dermatologic manifestations</strong> – Dermatologic manifestations include larva currens (<a class="graphic graphic_picture graphicRef122444" href="/z/d/graphic/122444.html" rel="external">picture 2</a>), pruritus, urticaria, and angioedema.</p><p></p><p class="bulletIndent1">Larva currens ("running" larva) presents as raised, pink, pruritic, evanescent streaks along the lower trunk, thighs, and buttocks, resulting from migrating larvae through the subcutaneous tissues (<a class="graphic graphic_picture graphicRef122444" href="/z/d/graphic/122444.html" rel="external">picture 2</a>) [<a href="#rid56">56</a>]. Larva currens can progress approximately 1 cm in 5 minutes and 5 to 15 cm per hour. As the larvae move, they leave behind a thin red line that gradually fades to brown and disappears within 48 hours. While larva currens is pathognomonic for strongyloidiasis, it is uncommon. In contrast, urticaria is more frequent [<a href="#rid55">55,57</a>]. At times, urticaria may be the sole clinical manifestation of chronic strongyloidiasis [<a href="#rid58">58</a>]. In an allergy clinic in New York City, among 84 subjects who had positive strongyloides enzyme-linked immunosorbent assays (ELISA) tests, 52 (61.9 percent) experienced cutaneous manifestation (pruritus, urticaria, angioedema, and/or rash) and half of these experienced symptomatic improvement after treatment with <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a> [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Respiratory symptoms</strong> – Respiratory symptoms include dry cough, throat irritation, dyspnea, and wheezing. Asthma that paradoxically worsens with corticosteroid use may occur [<a href="#rid60">60-62</a>]. </p><p></p><p>Eosinophilia may be observed, in the presence or absence of symptoms (see <a class="local">'Laboratory findings'</a> below). While eosinophilia may be indicative of strongyloidiasis, the absence of eosinophilia does not exclude infection with strongyloides or other intestinal helminths [<a href="#rid63">63</a>].</p><p>A meta-analysis aiming to describe the pattern and frequency of clinical and laboratory characteristics associated with <em>S. stercoralis </em>infection showed that symptoms were reported in 50.4 percent of cases, more often in nonendemic than endemic areas (58 versus 36 percent), and almost 70 percent had eosinophilia [<a href="#rid64">64</a>].</p><p class="headingAnchor" id="H974799588"><span class="h3">Severe manifestations</span><span class="headingEndMark"> — </span>Severe manifestations of strongyloidiasis include hyperinfection and disseminated infection; these occur in a minority of cases and are usually associated with immunosuppression. (See <a class="local">'Risk factors for severe disease'</a> above.)</p><p>Hyperinfection refers to accelerated autoinfection; signs and symptoms are attributable to increased larval migration within the organs normally involved in the autoinfection cycle (ie, the GI tract, lungs, and skin) (<a class="graphic graphic_figure graphicRef87284" href="/z/d/graphic/87284.html" rel="external">figure 1</a>). </p><p>Disseminated disease consists of hyperinfection syndrome with spread of larvae to organs and tissues outside those in the autoinfection cycle; these may include the liver, gallbladder, pancreas, kidneys, ovaries, mesenteric lymph nodes, diaphragm, heart, brain, and skeletal muscle [<a href="#rid4">4</a>]. At times, adult worms localize in the bronchial tree and lay eggs that develop into larvae. </p><p>Severe manifestations involving the GI tract, respiratory tract, and skin include:</p><p class="bulletIndent1"><span class="glyph">●</span>GI symptoms reflecting the presence of large quantities of larvae in the intestinal lumen; they are nonspecific and include abdominal pain (crampy or bloating in nature), watery diarrhea, constipation, anorexia, weight loss, difficulty swallowing, nausea, and vomiting. Electrolyte disturbances, inflammation, bleeding, ulceration, and small bowel obstruction may occur; fever and hemodynamic instability should prompt suspicion for perforation. Colitis and proctitis may be associated with occult or gross blood. Additional manifestations may include protein-losing enteropathy or ascites. Abdominal radiographic imaging may demonstrate paralytic ileus with dilated, thickened bowel loops (in the absence of evidence for mechanical obstruction), and/or small bowel distension with air-fluid levels. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory symptoms usually reflect the irritative responses related to the passage of larvae; these may include fever, dyspnea, cough, wheezing, choking, hoarseness, chest pain, hemoptysis, and palpitations [<a href="#rid65">65</a>]. Acute respiratory distress syndrome can occur during severe disease, usually in the setting of multiorgan failure. Chest radiographic imaging may demonstrate bilateral or focal interstitial infiltrates reflecting alveolar hemorrhage (<a class="graphic graphic_diagnosticimage graphicRef97783" href="/z/d/graphic/97783.html" rel="external">image 1</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dermatologic findings include larva currens on the lower trunk, thighs, and buttocks. In addition, widespread petechial and purpuric lesions may develop. Periumbilical purpura may be a pathognomonic manifestation of disseminated infection; it refers to radiation of purpura from the umbilical area and resembles thumbprints [<a href="#rid66">66,67</a>]. </p><p></p><p>Migration of filariform larvae during autoinfection may facilitate entry of enteric organisms into the systemic circulation. Clinically, this may manifest as extraintestinal bacterial infection such as pneumonia, meningitis, or sepsis; therefore, presence of fever and/or hemodynamic instability should prompt evaluation for systemic bacterial infection [<a href="#rid68">68</a>]. In such cases, bacterial cultures (from the blood, sputum, spinal fluid, or other sites) may demonstrate enteric flora, and polymicrobial bacterial infection can occur.</p><p>Peripheral eosinophilia is usually absent in the setting of hyperinfection and disseminated infection. (See <a class="local">'Laboratory findings'</a> below.)</p><p>Strongyloidiasis is not common among patients with HIV infection; however, hyperinfection/disseminated strongyloidiasis has been described as a manifestation of immune reconstitution inflammatory syndrome [<a href="#rid69">69,70</a>]. </p><p class="headingAnchor" id="H3440085908"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>Given the broad range of clinical manifestations, physical examination should include multisystem evaluation, particularly the chest, abdomen, skin, and central nervous system. Specific findings are described above. (See <a class="local">'Signs and symptoms'</a> above.) </p><p class="headingAnchor" id="H2066061928"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>In the setting of chronic infection, eosinophilia may be observed in approximately two-thirds of cases, in the presence or absence of symptoms [<a href="#rid71">71,72</a>]. In one report of refugees to the United States from Southeast Asia, eosinophilia (&gt;400 cells/mL) was associated with a diagnosis of strongyloidiasis [<a href="#rid71">71</a>]. However, the sensitivity of eosinophilia for strongyloidiasis was low; no eosinophilia was observed among patients with positive <em>Strongyloides</em> polymerase chain reaction in 27 percent of cases. </p><p>In the setting of the hyperinfection syndrome, peripheral eosinophilia is usually absent; more often there is suppression of peripheral eosinophil levels, sometimes related to corticosteroid therapy or concomitant bacterial infection. The presence of peripheral eosinophilia during hyperinfection appears to predict a better prognosis [<a href="#rid73">73,74</a>]. </p><p>Variable elevated serum IgE levels have been observed in 39 to 58 percent of cases [<a href="#rid75">75</a>]. This finding is generally not observed among patients with human T-lymphotropic virus type I (HTLV-I) and strongyloidiasis, however, which may be related to impaired ability of patients with HTLV-I infection to clear <em>S. stercoralis</em> infection [<a href="#rid76">76-78</a>]. </p><p class="headingAnchor" id="H2541238786"><span class="h2">Endoscopic findings</span><span class="headingEndMark"> — </span>There is no role for routine endoscopy for diagnosis of strongyloidiasis. For patients with GI symptoms of uncertain etiology who undergo endoscopy, it may be possible to establish a diagnosis of strongyloidiasis. </p><p>Endoscopic features of strongyloidiasis include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duodenum</strong> – Edema, brown mucosal discoloration, erythematous spots, subepithelial hemorrhages, and megaduodenum. Biopsy may demonstrate parasites in the gastric crypts or duodenal glands and eosinophilic infiltration of the lamina propria [<a href="#rid79">79-82</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Colon</strong> – Edema, loss of vascular pattern, aphthous ulcers, erosions, serpiginous ulcerations, and xanthoma-like lesions (<a class="graphic graphic_picture graphicRef51753" href="/z/d/graphic/51753.html" rel="external">picture 3</a>). <em>Strongyloides</em> colitis may mimic ulcerative colitis [<a href="#rid83">83</a>]. (See <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stomach</strong> – Thickened folds and mucosal erosions [<a href="#rid82">82,84</a>].</p><p></p><p class="headingAnchor" id="H349686373"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Diagnosis of chronic strongyloidiasis can be challenging given the low sensitivity of stool microscopy, low specificity of serology, and the lack of wide availability deoxyribonucleic acid (DNA)-based methods. Diagnosis of hyperinfection syndrome/disseminated infection is less difficult, given the florid clinical presentation and the large numbers of larvae often seen in the stool or other body fluids. </p><p>Issues related to diagnosis of symptomatic patients are discussed in the following section; issues related to screening of asymptomatic individuals are discussed below. (See <a class="local">'Asymptomatic individuals'</a> below.)</p><p class="headingAnchor" id="H2948883669"><span class="h2">Clinical approach</span><span class="headingEndMark"> — </span>Strongyloidiasis should be suspected among patients with relevant epidemiologic exposure (eg, skin contact with contaminated soil in tropical and subtropical regions) and gastrointestinal (GI), respiratory, and/or dermatologic manifestations (with or without eosinophilia) [<a href="#rid4">4,5</a>]. The diagnosis also warrants consideration in patients with systemic infection due to enteric organisms with no obvious cause [<a href="#rid85">85-87</a>]. </p><p>Laboratory tools for diagnosis of strongyloidiasis include stool testing and serology. The clinical approach depends on the clinical circumstances:</p><p class="bulletIndent1"><span class="glyph">●</span>For asymptomatic patients with suspected chronic infection, the approach is discussed below. (See <a class="local">'Asymptomatic individuals'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with dermatologic manifestations, respiratory manifestations, and/or eosinophilia (in the absence of GI symptoms), we favor serologic testing. For patients with dermatologic manifestations, skin biopsy may demonstrate larvae. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with GI symptoms, we favor serologic testing as well as stool testing. Stool microscopy allows evaluation for strongyloidiasis as well as other causes of GI symptoms, although the sensitivity is low. For settings in which stool polymerase chain reaction (PCR) is available, this assay is preferable given its relatively high sensitivity and specificity. As an alternative, stool can be sent for agar plate culture. (See <a class="local">'Stool studies'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with suspected hyperinfection syndrome, we favor serologic testing as well as stool testing. In addition, blood cultures should be obtained to rule out secondary bacterial infection. We also pursue diagnostic testing tailored to clinical manifestations:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with respiratory symptoms should undergo chest radiography as well as evaluation of respiratory specimens; larvae may be observed in sputum, bronchoalveolar lavage fluid, or pleural fluid [<a href="#rid88">88,89</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with ascites should undergo paracentesis with evaluation for larvae in peritoneal fluid. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with neurologic symptoms should undergo lumbar puncture to assess cerebrospinal fluid for larvae as well as findings consistent with meningitis (See  <a class="medical medical_review" href="/z/d/html/1287.html" rel="external">"Clinical features and diagnosis of acute bacterial meningitis in adults"</a>.)</p><p></p><p class="headingAnchor" id="H2946571683"><span class="h2">Stool studies</span><span class="headingEndMark"> — </span>The traditional diagnostic approach consists of microscopy for direct identification of <em>S. stercoralis</em> larvae in stool; this is still done in many laboratories, but the sensitivity is relatively low (&lt;50 percent) given intermittent larval excretion. Larvae may be detectable in stool three to four weeks after dermal penetration (<a class="graphic graphic_picture graphicRef63898" href="/z/d/graphic/63898.html" rel="external">picture 1</a>) [<a href="#rid90">90</a>]. </p><p>Other stool testing approaches include agar plate culture, sedimentation concentration, Baermann concentration with charcoal culture, and Harada-Mori filter paper technique [<a href="#rid91">91,92</a>]. These specialized techniques are rarely available in most diagnostic microbiology laboratories and have not been employed in most studies that report treatment efficacy [<a href="#rid93">93</a>]. </p><p>Of the above techniques, agar plate culture is most sensitive; however, assessing the accuracy is difficult given lack of a gold standard for diagnosis [<a href="#rid94">94-96</a>]. This method involves inoculating agar plates with stool and incubating for two days at room temperature [<a href="#rid97">97</a>]; such testing can be performed at the United States Centers for Disease Control and Prevention [<a href="#rid98">98</a>]. Larvae crawl on the agar and spread bacteria in their paths, creating bacterial growth patterns on the agar surface. Larvae may be observed by macroscopic examination of the plates; their presence can be confirmed by washing the plate surface with formalin and examining the washing sediment [<a href="#rid99">99</a>].</p><p>The sensitivity of stool detection may be improved with increased number of stool samples for examination; when as many as seven stool samples are studied, the sensitivity may approach 100 percent [<a href="#rid90">90,100</a>]. However, patterns of stool detection are variable among infected individuals. In one study including 108 asymptomatic Brazilian men with strongyloidiasis, eight weekly stool exams were performed without intervening treatment [<a href="#rid100">100</a>]. Among 29 men with detectable larvae in only one of the first four specimens, all of the next four samples were negative in 76 percent of cases. </p><p>Stool nucleic acid amplification tests (NAATs) have greater specificity for diagnosis of <em>Strongyloides</em> than direct stool examination [<a href="#rid4">4,101-103</a>]. In one systematic review of PCR for diagnosis of strongyloidiasis, the sensitivity and specificity were 72 and 93 percent, respectively [<a href="#rid104">104</a>]. However, sensitivity estimates vary widely depending on the DNA extraction and molecular methods used [<a href="#rid105">105</a>]. In some cases, suboptimal sensitivity may be attributable to intermittent larval production and presence of PCR inhibitors in stool. Use of stool NAATs for diagnosis of <em>Strongyloides</em> infection is limited by availability but is increasing, particularly with use of multiplex PCR for GI pathogens. </p><p class="headingAnchor" id="H14"><span class="h2">Serology</span><span class="headingEndMark"> — </span>Serologic tests may be used to overcome the limitations of stool testing, with greater sensitivity [<a href="#rid106">106</a>]. Serologic tests include enzyme-linked immunosorbent assays (ELISAs), indirect immunofluorescence microscopy, gelatin particle agglutination, and immunoblot. </p><p>Most serologic tests measure IgG or IgG4 response to a crude soluble extract of larvae obtained from experimentally infected animals or related <em>Strongyloides</em> species. Limitations include cross-reactivity in patients with filarial infection or infection due to other soil-transmitted helminths, diminished sensitivity in patients with hematologic malignancy or human T-lymphotropic virus type I infection, inability to distinguish between current and prior infection, and lack of standardization across centers [<a href="#rid99">99,107</a>]. Recombinant antigens have been used with improved diagnostic accuracy to overcome some of these limitations. In addition, using a combination of serologic tests may help increase specificity [<a href="#rid95">95</a>]. </p><p>The negative predictive value of serologic screening is higher among migrants than returning travelers [<a href="#rid108">108,109</a>]. In one study of two commercially available ELISAs, high sensitivity (89 and 83 percent, respectively) and specificity (97 percent) for diagnosis of chronic infection were reported [<a href="#rid110">110</a>]. Another study compared two ELISA assays and a luciferase immunoprecipitation system (LIPS) assay for detection of IgG antibodies to S. stercoralis among 101 serum samples; agreement between all three assays was observed in 65 percent of cases, and each method had similar numbers of positive samples (84 to 89 percent) [<a href="#rid111">111</a>]. In another study including 86 patients with microscopically proven strongyloidiasis, serologic testing was associated with 81 percent sensitivity [<a href="#rid108">108</a>]. </p><p>ELISAs for detection of <em>Strongyloides</em> antigens are being refined, including via multiplexed antigen detection assays [<a href="#rid112">112</a>]. Immunochromatographic tests (ICTs) for the diagnosis of <em>S. stercoralis</em> infection are also being developed. In one study of sera from 274 migrants from sub-Saharan Africa, ICT had a sensitivity and specificity of 82 and 74 percent, respectively, compared with stool agar plate culture and/or PCR [<a href="#rid113">113</a>]. Future optimization of ICTs may enable their use for screening purposes. </p><p>Urine testing for strongyloides-specific IgG by ELISA has also been evaluated, with studies suggesting it to have a diagnostic accuracy comparable with serologic assay, being more sensitive than fecal methods and with minimal daily variation [<a href="#rid114">114,115</a>]. Concentrated-urine ELISA testing is also being evaluated for diagnosis of <em>Strongyloides </em>[<a href="#rid116">116</a>].</p><p class="headingAnchor" id="H16"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of uncomplicated strongyloidiasis includes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ascariasis and hookworm</strong> – Strongyloidiasis, ascariasis, and hookworm can all cause nonspecific gastrointestinal and/or pulmonary symptoms or chronic urticaria and/or pruritus. In addition, all can be associated with eosinophilia in the presence or absence of other symptoms. Coinfection can occur; the diagnoses are distinguished by stool microscopy. (See  <a class="medical medical_review" href="/z/d/html/14001.html" rel="external">"Approach to stool microscopy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cutaneous larva migrans (CLM) </strong>– Larva currens, the dermatologic manifestation of strongyloidiasis, must be distinguished from CLM; both are associated with migratory serpiginous lesions that are erythematous, raised, and pruritic. Usually the conditions can be distinguished clinically based on the speed of advancement; larva currens can progress approximately 1 cm in 5 minutes and 5 to 15 cm per hour, while the larval track of cutaneous larva migrans progresses approximately 1 to 2 cm per day. Additionally, larva currens is typically evanescent and pink, whereas CLM is angry-looking, red, raised, and typically persists for weeks. (See  <a class="medical medical_review" href="/z/d/html/5718.html" rel="external">"Hookworm-related cutaneous larva migrans"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ulcerative colitis</strong> – <em>Strongyloides</em> colitis may mimic ulcerative colitis; distinctive features of strongyloidiasis include skip pattern of inflammation, distal attenuation of the disease, eosinophil-rich infiltrates, relatively intact crypt architecture, and frequent involvement of submucosa with erythematous nodules (<a class="graphic graphic_picture graphicRef51753" href="/z/d/graphic/51753.html" rel="external">picture 3</a>) [<a href="#rid83">83</a>]. (See  <a class="medical medical_review" href="/z/d/html/4067.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults"</a>.)</p><p></p><p>The differential diagnosis of hyperinfection syndrome/disseminated disease includes: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Loeffler syndrome</strong> – Besides <em>S. stercoralis</em>, other helminths with life cycles in which infecting larvae migrate the lungs via the bloodstream and penetrate into alveoli include <em>Ascaris (A. lumbricoides</em>, <em>A. suum</em>) and hookworms (<em>Ancylostoma duodenale</em>, <em>Necator americanus</em>). Loeffler syndrome refers to transient pulmonary radiographic opacities and peripheral blood eosinophilia in the setting of ascariasis. (See  <a class="medical medical_review" href="/z/d/html/5715.html" rel="external">"Overview of pulmonary eosinophilia", section on 'Transpulmonary passage of helminth larvae (Löffler syndrome)'</a> and  <a class="medical medical_review" href="/z/d/html/5673.html" rel="external">"Ascariasis", section on 'Early phase: Pulmonary manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tropical filarial pulmonary eosinophilia</strong> – Tropical filarial pulmonary eosinophilia occurs in the context of lymphatic filariasis; symptoms include dry cough, wheeze, and fatigue. Tropical pulmonary eosinophilia is characterized by eosinophilia above 3000/microL; the diagnosis can be confirmed by filarial antibody titers. (See  <a class="medical medical_review" href="/z/d/html/5711.html" rel="external">"Tropical pulmonary eosinophilia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Meningococcal meningitis</strong> – Both meningococcal meningitis and strongyloidiasis may present with neurologic manifestations, purpura, and hemodynamic instability. The diagnosis of meningococcal meningitis is established via lumbar puncture. (See  <a class="medical medical_review" href="/z/d/html/1300.html" rel="external">"Clinical manifestations of meningococcal infection"</a> and  <a class="medical medical_review" href="/z/d/html/1281.html" rel="external">"Diagnosis of meningococcal infection"</a>.)</p><p></p><p class="headingAnchor" id="H17"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Treatment with anthelminthic therapy is warranted for symptomatic and asymptomatic individuals, regardless of immune status. The goal of treatment is cure, in order to prevent development of severe disease in the context of chronic autoinfection. </p><p>Issues related to treatment of symptomatic patients are discussed in the following section; issues related to treatment of asymptomatic individuals are discussed below. (See <a class="local">'Asymptomatic individuals'</a> below.)</p><p class="headingAnchor" id="H3351053712"><span class="h2">Initial approach</span></p><p class="headingAnchor" id="H2426065651"><span class="h3">Uncomplicated infection</span><span class="headingEndMark"> — </span>For patients with uncomplicated strongyloidiasis, we favor treatment with <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a>:</p><p class="bulletIndent1"><span class="glyph">●</span>For immunocompetent patients, we favor a single-dose or two-dose regimen (200 mcg/kg per day for one or two days) [<a href="#rid4">4,117,118</a>]. The approach to regimen selection varies among experts; data supporting either approach are limited. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For immunocompromised patients, we favor a four-dose regimen (200 mcg/kg daily for two days, repeated at two weeks [eg, one autoinfection cycle]), given the potentially devastating nature of <em>Strongyloides</em> infection in the setting of immunosuppression and the high tolerability of <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a>, even though clinical data to support this approach are lacking. </p><p></p><p><a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">Ivermectin</a> is lipophilic. In individuals with higher body mass index, this can result in lower plasma levels; however, this can also result in a longer half-life and time to clearance [<a href="#rid119">119-121</a>]. The clinical impact of these effects on treatment efficacy is unknown; given the lipophilicity, we favor dosing based on actual body weight. </p><p>Following treatment, follow-up monitoring should be performed as described below. (See <a class="local">'Follow-up'</a> below.)</p><p>For individuals from areas of Africa endemic for loiasis, screening for loiasis<em> </em>microfilaremia (via blood smear) should be performed prior to administration of <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a>; administration of ivermectin to highly microfilaremic patients can precipitate life-threatening encephalopathy. (See  <a class="medical medical_review" href="/z/d/html/5684.html" rel="external">"Loiasis (Loa loa infection)"</a>.)</p><p>The efficacy of <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a> (200 mcg/kg per day for one or two days) has been shown to be greater than that of <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> (400 mg twice a day for three to seven days) and comparable with that of thiabendazole (25 mg/kg per day for three days) [<a href="#rid117">117,122</a>]. In a meta-analysis including seven trials and more than 1100 patients with chronic strongyloidiasis, cure rates for ivermectin were superior to albendazole and comparable with thiabendazole (74 to 84 percent, 48 percent, and 69 percent, respectively) [<a href="#rid117">117</a>]. Use of thiabendazole is limited by gastrointestinal adverse effects and drug availability. </p><p>Data comparing single-dose and two-dose <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a> regimens are limited, and the available tools to assess treatment response (stool exams and serologic titer) have limited specificity. In one randomized trial including 31 patients treated with single-dose therapy and 29 patients treated with two-dose therapy, treatment failure (assessed via stool exam) was observed in 3.2 versus 6.9 percent, respectively [<a href="#rid122">122</a>]. In another randomized trial including 16 patients treated with single-dose ivermectin and 18 patients treated with two-dose ivermectin, there were no cases of treatment failure (assessed via stool exam) [<a href="#rid123">123</a>]. </p><p><a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">Ivermectin</a> failure has been observed, even in immunocompetent hosts. For this reason, a four-dose regimen of ivermectin (two doses administered two weeks apart) has been proposed, since the duration of the autoinfection cycle is two weeks [<a href="#rid118">118,124-126</a>]. However, thus far, available data do not suggest superior efficacy for a four-dose regimen over a one-dose regimen. In a randomized trial including more than 300 patients in nonendemic areas with positive serology (high titer) or positive serology (any titer) plus positive stool test, patients were randomly assigned to one-dose or four-dose ivermectin treatment [<a href="#rid127">127</a>]. After 12 months, the response rate (assessed via fall in serologic titer) was comparable between the groups (86 versus 85 percent, respectively). Mild adverse events occurred more frequently among those in the four-dose cohort. </p><p class="headingAnchor" id="H21"><span class="h3">Severe disease</span><span class="headingEndMark"> — </span>For patients with known or suspected hyperinfection/disseminated strongyloidiasis, treatment with <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a> (200 mcg/kg per day) should be initiated, as should empiric antibiotic therapy with activity against enteric gram-negative bacteria. In addition, patients on immunosuppressive agents should have these regimens reduced, if feasible. (See  <a class="medical medical_review" href="/z/d/html/3149.html" rel="external">"Gram-negative bacillary bacteremia in adults"</a>.)</p><p>The optimal duration of <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a> for hyperinfection/disseminated strongyloidiasis is uncertain; we favor treatment for at least two weeks, tailored to individual circumstances. For patients with persistent immunosuppression or critical illness in the setting of persistently positive stool examination for ≥3 days on ivermectin monotherapy, many experts would switch from ivermectin monotherapy to combination treatment with ivermectin plus <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> until clinical improvement is observed [<a href="#rid128">128</a>]. </p><p>We continue anthelminthic treatment until symptoms have resolved and daily stool examination is negative for at least two weeks (one autoinfection cycle). For patients with persistent immunosuppression whose symptoms have resolved, we favor administration of suppressive <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a> once monthly for at least six months [<a href="#rid129">129</a>]. </p><p>For patients unable to take <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a> orally or via nasogastric tube (eg, due to severe systemic illness or paralytic ileus), ivermectin may be administered subcutaneously [<a href="#rid130">130,131</a>]. Rectal administration has also been used successfully as an alternative in such cases [<a href="#rid132">132</a>], although some data suggest that rectal suppositories of ivermectin may not achieve sufficient serum levels [<a href="#rid133">133</a>].</p><p>Patients with hyperinfection/disseminated infection that does not resolve after initial treatment should be evaluated for an underlying immune defect such as human T-lymphotropic virus type I infection. (See  <a class="medical medical_review" href="/z/d/html/8317.html" rel="external">"Human T-lymphotropic virus type I: Disease associations, diagnosis, and treatment", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H2578238992"><span class="h2">Follow-up</span><span class="headingEndMark"> — </span>Following completion of treatment, our follow-up approach is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with persistent symptoms following completion of treatment, we favor repeat treatment as described below. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with positive stool examination prior to treatment, we perform repeat stool examination two to four weeks after treatment. Patients with persistently positive stool examination warrant repeat treatment as described below. However, a negative stool exam is not definitive proof of parasitologic cure, since the sensitivity of stool examination is relatively low. (See <a class="local">'Stool studies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with positive stool polymerase chain reaction (PCR) prior to treatment, we do not favor follow-up stool PCR testing; the role of stool PCR for follow-up monitoring is uncertain [<a href="#rid118">118</a>]. (See <a class="local">'Stool studies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with eosinophilia prior to treatment, we perform repeat complete blood counts with differential every three months for up to twelve months. In one study including 31 patients treated for strongyloidiasis, reductions in peripheral eosinophilia was observed after an average of 96 days [<a href="#rid134">134</a>]. </p><p></p><p class="bulletIndent1">Persistent eosinophilia up to twelve months after following treatment may reflect failure to eradicate strongyloidiasis and/or an alternative etiology [<a href="#rid135">135</a>]. Such patients should be evaluated for alternative causes of eosinophilia; if none is identified, a repeat course of treatment for strongyloidiasis is reasonable. (See  <a class="medical medical_review" href="/z/d/html/5691.html" rel="external">"Approach to the patient with unexplained eosinophilia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with positive serology prior to treatment, use of serologic monitoring for follow-up should be guided by the type of assay used. For some assays, successful treatment has been associated with falling immunoreactivity at three to six months [<a href="#rid134">134,136,137</a>]; however, for other assays, use of serologic monitoring for follow-up is hampered by lack of standardization.</p><p></p><p>The optimal approach to repeat treatment in the setting of treatment failure is uncertain; reasonable approaches include a repeat two-dose <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a> regimen (200 mcg/kg per day for two days) or a four-dose ivermectin regimen (200 mcg/kg daily for two days, repeated at two weeks).</p><p>Patients with treatment failure should be evaluated for human T-lymphotropic virus type I infection [<a href="#rid138">138,139</a>]. (See  <a class="medical medical_review" href="/z/d/html/8317.html" rel="external">"Human T-lymphotropic virus type I: Disease associations, diagnosis, and treatment"</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Among patients with hyperinfection/disseminated infection, the mortality rate is up to 70 to 100 percent; Factors that increase the likelihood of mortality include concomitant immunosuppression, bacteremia, and delayed diagnosis [<a href="#rid4">4,140,141</a>]. </p><p class="headingAnchor" id="H4157775412"><span class="h1">ASYMPTOMATIC INDIVIDUALS</span></p><p class="headingAnchor" id="H2525271111"><span class="h2">Screening</span><span class="headingEndMark"> — </span>Serologic screening of asymptomatic individuals for strongyloidiasis is warranted in the following circumstances [<a href="#rid6">6,16,134,142-147</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with relevant epidemiologic exposure (eg, skin contact with contaminated soil in tropical and subtropical regions) who are undergoing medical interventions associated with immunosuppression (including solid organ transplantation, hematopoietic stem cell transplantation, or administration of corticosteroids, cytotoxic drugs, or tumor necrosis factor inhibitors). (See <a class="local">'Geography'</a> above and <a class="local">'Risk factors for severe disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Organ donors with relevant epidemiologic exposure (eg, skin contact with contaminated soil in tropical and subtropical regions). (See  <a class="medical medical_review" href="/z/d/html/1398.html" rel="external">"Evaluation for infection before solid organ transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/1399.html" rel="external">"Evaluation for infection before hematopoietic cell transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Military personnel with history of service in areas where strongyloidiasis is endemic (even in the setting of remote exposure).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immigrants and refugees. (See  <a class="medical medical_review" href="/z/d/html/13959.html" rel="external">"Medical care of adult refugees, immigrants, and migrants"</a>.)</p><p></p><p>For screening asymptomatic patients with suspected chronic infection, we favor serologic testing; stool testing is not sufficiently sensitive [<a href="#rid94">94</a>]. For asymptomatic patients who are embarking on immunosuppressive therapy, we perform serologic testing followed by prompt administration of empiric treatment (eg, before the results of serologic testing are available). (See <a class="local">'Preventive treatment'</a> below.)</p><p>For transplant candidates and transplant recipients diagnosed with strongyloidiasis, we perform serologic screening for human T-lymphotropic virus type I infection [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/z/d/html/8317.html" rel="external">"Human T-lymphotropic virus type I: Disease associations, diagnosis, and treatment"</a>.)</p><p>Issues related to risk factors for severe disease are discussed above. (See <a class="local">'Risk factors for severe disease'</a> above.)</p><p class="headingAnchor" id="H3212901495"><span class="h2">Preventive treatment</span><span class="headingEndMark"> — </span>The optimal approach to preventive treatment of individuals with asymptomatic strongyloidiasis is uncertain; in general, our approach is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with relevant epidemiologic exposure (eg, skin contact with contaminated soil in tropical and subtropical regions) who require prompt initiation of immunosuppression, we perform serologic testing and administer empiric preventive treatment for strongyloidiasis (<a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a> 200 mcg/kg daily for two days, repeated at two weeks) while test results are pending [<a href="#rid7">7</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with relevant epidemiologic exposure (eg, skin contact with contaminated soil in tropical and subtropical regions) who require immunosuppression but need not begin promptly (ie, there is sufficient time to pursue screening), we perform serologic testing; for patients with positive serologic test results, we administer preventive treatment for strongyloidiasis (<a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a> 200 mcg/kg daily for two days, repeated at two weeks) [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For organ transplant recipients whose organ donors have positive serologic testing for strongyloidiasis, we administer preventive treatment to the recipient (<a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a> 200 mcg/kg daily for two days, repeated at two weeks) [<a href="#rid27">27,148</a>]. For living donors (who are not otherwise immunosuppressed), we administer preventive treatment for strongyloidiasis (ivermectin 200 mcg/kg daily for two days).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with positive serologic test results who do not require immunosuppression (such as military personnel, immigrants, and refugees), we administer preventive treatment for strongyloidiasis (<a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a> 200 mcg/kg daily for two days).</p><p></p><p>For asymptomatic seropositive individuals who are receiving immunosuppressive therapy, we favor a four-dose preventive treatment regimen (single dose administered on two consecutive days, then repeated after one autoinfection cycle) rather than a two-dose regimen, given the potentially devastating nature of <em>Strongyloides</em> infection in the setting of immunosuppression and the high tolerability of <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a>; however, there is no clinical evidence to support this approach. For asymptomatic seropositive individuals who are not receiving immunosuppressive therapy, an empiric two-dose preventive treatment regimen (ivermectin 200 mcg/kg daily for two days) is reasonable. </p><p class="headingAnchor" id="H25"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – Strongyloidiasis is caused by infection with the helminth <em>Strongyloides stercoralis</em>. This organism is capable of completing its life cycle entirely within the human host. Therefore, chronic asymptomatic infection can be sustained for decades, and clinical manifestations can occur long after the initial infection. In addition, among patients with subclinical infection who subsequently become immunosuppressed, larval reproduction can lead to disseminated infection. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Strongyloidiasis is endemic in rural areas of tropical and subtropical regions; in these areas, the overall regional prevalence may exceed 25 percent. In addition, strongyloidiasis occurs sporadically in temperate areas such as North America, southern Europe, Japan, and Australia. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Life cycle</strong> – The life cycle begins when human skin contacts filariform larvae (the infective larval stage) of <em>S. stercoralis</em>, which are found in soil or other materials contaminated with human stool (<a class="graphic graphic_figure graphicRef87284" href="/z/d/graphic/87284.html" rel="external">figure 1</a>). The filariform larvae penetrate the skin and migrate via the bloodstream and lymphatics to the lungs, where they penetrate into the alveolar air sacs. The larvae then ascend the tracheobronchial tree and are swallowed. In addition, autoinfection can occur; in this part of the life cycle, the rhabditiform larvae become infective filariform larvae within the human gastrointestinal (GI) tract. (See <a class="local">'Life cycle and autoinfection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors for severe disease</strong> – Immunosuppressed individuals are at risk for developing <em>Strongyloides</em> hyperinfection/disseminated disease; this can occur as a consequence of accelerated autoinfection even in the setting of a remote history of initial infection. Risk factors include conditions associated with impairment of cell-mediated immunity and medical interventions associated with immunosuppression. (See <a class="local">'Risk factors for severe disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations and laboratory findings</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acute and chronic infection</strong> – Strongyloidiasis may be asymptomatic or associated with nonspecific complaints in more than half of cases. Signs and symptoms of acute and chronic infection may include GI symptoms, respiratory symptoms, and dermatologic manifestations (<a class="graphic graphic_picture graphicRef122444" href="/z/d/graphic/122444.html" rel="external">picture 2</a>). In the setting of chronic infection, eosinophilia may be observed in approximately two-thirds of cases (in the presence or absence of symptoms). (See <a class="local">'Signs and symptoms'</a> above and <a class="local">'Laboratory findings'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe manifestations</strong> – Severe manifestations of strongyloidiasis include hyperinfection and disseminated infection; these occur in a minority of cases and are usually associated with immunosuppression. Hyperinfection refers to accelerated autoinfection; signs and symptoms are attributable to increased larval migration within the organs normally involved in the autoinfection cycle (ie, the GI tract, lungs, and skin). Disseminated disease consists of hyperinfection with spread of larvae to organs and tissues outside those in the autoinfection cycle. Larval migration may facilitate entry of enteric organisms into the systemic circulation; this may manifest clinically as extraintestinal bacterial infection such as pneumonia, meningitis, or sepsis. In the setting of severe disease, peripheral eosinophilia is usually absent. (See <a class="local">'Severe manifestations'</a> above and <a class="local">'Laboratory findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– (see <a class="local">'Diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical approach</strong> – Strongyloidiasis should be suspected in patients with relevant epidemiologic exposure (eg, skin contact with contaminated soil in tropical and subtropical regions) and GI, respiratory, and/or dermatologic manifestations (with or without eosinophilia). The diagnosis also warrants consideration in patients with systemic infection due to enteric organisms with no obvious cause. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laboratory testing</strong> – Laboratory tools for diagnosis of strongyloidiasis include stool testing and serology. In general, the preferred diagnostic approach consists of serologic testing. For patients with GI symptoms and for patients with suspected hyperinfection syndrome, we also perform stool testing. Additional diagnostic testing should be tailored to clinical manifestations. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – For patients with strongyloidiasis, we suggest treatment with <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a> rather than alternative agents (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>) (see <a class="local">'Management'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immunocompetent patients</strong> – For immunocompetent patients with uncomplicated strongyloidiasis, we suggest a single-dose or two-dose regimen over a longer regimen (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The approach to regimen selection varies among experts; data supporting either approach are limited. (See <a class="local">'Uncomplicated infection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immunocompromised patients</strong> – For immunocompromised patients with uncomplicated strongyloidiasis, we suggest a four-dose regimen (200 mcg/kg daily for two days, repeated at two weeks) over a shorter regimen (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), given the potentially devastating nature of <em>Strongyloides</em> infection in the setting of immunosuppression and the high tolerability of <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a>. (See <a class="local">'Uncomplicated infection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hyperinfection/disseminated infection</strong> – For patients with known or suspected hyperinfection/disseminated strongyloidiasis, the optimal duration of <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a> is uncertain; we favor treatment for at least two weeks and continue until symptoms have resolved and daily stool examination is negative for at least two weeks (one autoinfection cycle); a longer duration of treatment may be warranted for patients with persistent immunosuppression. In addition, we initiate empiric antibiotic therapy with activity against enteric gram-negative bacteria. Patients on immunosuppressive agents should have these regimens reduced, if feasible. (See <a class="local">'Severe disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening </strong>– (see <a class="local">'Screening'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Whom to screen</strong> – Serologic screening of asymptomatic individuals for strongyloidiasis is warranted for patients with relevant epidemiologic exposure who are undergoing medical interventions associated with immunosuppression, organ donors with relevant epidemiologic exposure, military personnel with history of service in endemic areas, and immigrants and refugees with relevant epidemiologic exposure. (See <a class="local">'Screening'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical approach</strong> – For asymptomatic patients with relevant epidemiologic exposure who require prompt initiation of immunosuppression, we perform serologic testing and administer empiric preventive <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a> while test results are pending. For asymptomatic patients with relevant epidemiologic exposure who require immunosuppression but need not begin promptly (ie, there is sufficient time to pursue screening), we perform serologic testing and administer empiric preventive ivermectin for those with positive results. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preventive treatment</strong> – For preventive treatment of asymptomatic patients with strongyloidiasis who require immunosuppression, we suggest a four-dose <a class="drug drug_general" data-topicid="8641" href="/z/d/drug information/8641.html" rel="external">ivermectin</a> regimen over a shorter regimen (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), given the potentially devastating nature of <em>Strongyloides</em> infection in the setting of immunosuppression and the high tolerability of ivermectin. For preventive treatment of asymptomatic immunocompetent patients with strongyloidiasis, we suggest a two-dose regimen (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Preventive treatment'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Munisankar S, Rajamanickam A, Balasubramanian S, et al. Seroprevalence of Strongyloides stercoralis infection in a South Indian adult population. PLoS Negl Trop Dis 2022; 16:e0010561.</a></li><li><a class="nounderline abstract_t">Czeresnia JM, Weiss LM. Strongyloides stercoralis. Lung 2022; 200:141.</a></li><li><a class="nounderline abstract_t">Buonfrate D, Bisanzio D, Giorli G, et al. The Global Prevalence of Strongyloides stercoralis Infection. Pathogens 2020; 9.</a></li><li><a class="nounderline abstract_t">Krolewiecki A, Nutman TB. Strongyloidiasis: A Neglected Tropical Disease. Infect Dis Clin North Am 2019; 33:135.</a></li><li><a class="nounderline abstract_t">Jourdan PM, Lamberton PHL, Fenwick A, Addiss DG. Soil-transmitted helminth infections. Lancet 2018; 391:252.</a></li><li><a class="nounderline abstract_t">Requena-Méndez A, Buonfrate D, Gomez-Junyent J, et al. Evidence-Based Guidelines for Screening and Management of Strongyloidiasis in Non-Endemic Countries. Am J Trop Med Hyg 2017; 97:645.</a></li><li><a class="nounderline abstract_t">La Hoz RM, Morris MI, AST Infectious Diseases Community of Practice. Intestinal parasites including Cryptosporidium, Cyclospora, Giardia, and Microsporidia, Entamoeba histolytica, Strongyloides, Schistosomiasis, and Echinococcus: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33:e13618.</a></li><li><a class="nounderline abstract_t">Schär F, Trostdorf U, Giardina F, et al. Strongyloides stercoralis: Global Distribution and Risk Factors. PLoS Negl Trop Dis 2013; 7:e2288.</a></li><li><a class="nounderline abstract_t">Balen Topić M, Marjanović E, Tomasović D, Sviben M. Is strongyloidiasis currently autochthonous in Croatia? A retrospective study. Trans R Soc Trop Med Hyg 2021; 115:1298.</a></li><li><a class="nounderline abstract_t">Bronstein AM, Lukashev AN, Maximova MS, Sacharova TV. The autochthonous cases of acute strongyloidiasis in the Moscow region. Germs 2021; 11:116.</a></li><li><a class="nounderline abstract_t">Ottino L, Buonfrate D, Paradies P, et al. Autochthonous Human and Canine Strongyloides stercoralis Infection in Europe: Report of a Human Case in An Italian Teen and Systematic Review of the Literature. Pathogens 2020; 9.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention. Notes from the field: Strongyloidiasis in a rural setting--Southeastern Kentucky, 2013. MMWR Morb Mortal Wkly Rep 2013; 62:843.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention. Notes from the field: strongyloides infection among patients at a long-term care facility--Florida, 2010-2012. MMWR Morb Mortal Wkly Rep 2013; 62:844.</a></li><li><a class="nounderline abstract_t">Bradbury RS, Lane M, Arguello I, et al. Parasitic Disease Surveillance, Mississippi, USA. Emerg Infect Dis 2021; 27:2201.</a></li><li><a class="nounderline abstract_t">Inagaki K, Bradbury RS, Hobbs CV. Hospitalizations Associated With Strongyloidiasis in the United States, 2003-2018. Clin Infect Dis 2022; 75:1548.</a></li><li><a class="nounderline abstract_t">Posey DL, Blackburn BG, Weinberg M, et al. High prevalence and presumptive treatment of schistosomiasis and strongyloidiasis among African refugees. Clin Infect Dis 2007; 45:1310.</a></li><li><a class="nounderline abstract_t">Gyorkos TW, Genta RM, Viens P, MacLean JD. Seroepidemiology of Strongyloides infection in the Southeast Asian refugee population in Canada. Am J Epidemiol 1990; 132:257.</a></li><li><a class="nounderline abstract_t">Lindrose AR, Mitra I, Fraser J, et al. Helminth infections in the US military: from strongyloidiasis to schistosomiasis. J Travel Med 2021; 28.</a></li><li><a class="nounderline abstract_t">Asundi A, Beliavsky A, Liu XJ, et al. Prevalence of strongyloidiasis and schistosomiasis among migrants: a systematic review and meta-analysis. Lancet Glob Health 2019; 7:e236.</a></li><li><a class="nounderline abstract_t">Salvador F, Treviño B, Bosch-Nicolau P, et al. Strongyloidiasis screening in migrants living in Spain: systematic review and meta-analysis. Trop Med Int Health 2020; 25:281.</a></li><li><a class="nounderline abstract_t">Gorgani-Firouzjaee T, Kalantari N, Chehrazi M, et al. Global prevalence of Strongyloides stercoralis in dogs: A systematic review and meta-analysis. J Helminthol 2022; 96:e11.</a></li><li><a class="nounderline abstract_t">Jaleta TG, Zhou S, Bemm FM, et al. Different but overlapping populations of Strongyloides stercoralis in dogs and humans-Dogs as a possible source for zoonotic strongyloidiasis. PLoS Negl Trop Dis 2017; 11:e0005752.</a></li><li><a class="nounderline abstract_t">Janwan P, Rodpai R, Intapan PM, et al. Possible transmission of Strongyloides fuelleborni between working Southern pig-tailed macaques (Macaca nemestrina) and their owners in Southern Thailand: Molecular identification and diversity. Infect Genet Evol 2020; 85:104516.</a></li><li><a class="nounderline abstract_t">Vazquez Guillamet LJ, Saul Z, Miljkovich G, et al. Strongyloides Stercoralis Infection Among Human Immunodeficiency Virus (HIV)-Infected Patients in the United States of America: A Case Report and Review of Literature. Am J Case Rep 2017; 18:339.</a></li><li><a class="nounderline abstract_t">Jones JM, Hill C, Briggs G, et al. Notes from the Field: Strongyloidiasis at a Long-Term-Care Facility for the Developmentally Disabled - Arizona, 2015. MMWR Morb Mortal Wkly Rep 2016; 65:608.</a></li><li><a class="nounderline abstract_t">Sugiyama K, Hasegawa Y, Nagasawa T, Hitomi S. Exposure of medical staff to Strongyloides stercolaris from a patient with disseminated strongyloidiasis. J Infect Chemother 2006; 12:217.</a></li><li><a class="nounderline abstract_t">Abanyie FA, Gray EB, Delli Carpini KW, et al. Donor-derived Strongyloides stercoralis infection in solid organ transplant recipients in the United States, 2009-2013. Am J Transplant 2015; 15:1369.</a></li><li><a class="nounderline abstract_t">Abad CLR, Bhaimia E, Schuetz AN, Razonable RR. A comprehensive review of Strongyloides stercoralis infection after solid organ and hematopoietic stem cell transplantation. Clin Transplant 2022; 36:e14795.</a></li><li><a class="nounderline abstract_t">Chu E, Whitlock WL, Dietrich RA. Pulmonary hyperinfection syndrome with Strongyloides stercoralis. Chest 1990; 97:1475.</a></li><li><a class="nounderline abstract_t">Pelletier LL Jr, Baker CB, Gam AA, et al. Diagnosis and evaluation of treatment of chronic strongyloidiasis in ex-prisoners of war. J Infect Dis 1988; 157:573.</a></li><li><a class="nounderline abstract_t">Keiser PB, Nutman TB. Strongyloides stercoralis in the Immunocompromised Population. Clin Microbiol Rev 2004; 17:208.</a></li><li><a class="nounderline abstract_t">Haque AK, Schnadig V, Rubin SA, Smith JH. Pathogenesis of human strongyloidiasis: autopsy and quantitative parasitological analysis. Mod Pathol 1994; 7:276.</a></li><li><a class="nounderline abstract_t">Ye L, Taylor GP, Rosadas C. Human T-Cell Lymphotropic Virus Type 1 and Strongyloides stercoralis Co-infection: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 2022; 9:832430.</a></li><li><a class="nounderline abstract_t">Celedon JC, Mathur-Wagh U, Fox J, et al. Systemic strongyloidiasis in patients infected with the human immunodeficiency virus. A report of 3 cases and review of the literature. Medicine (Baltimore) 1994; 73:256.</a></li><li><a class="nounderline abstract_t">Lessnau KD, Can S, Talavera W. Disseminated Strongyloides stercoralis in human immunodeficiency virus-infected patients. Treatment failure and a review of the literature. Chest 1993; 104:119.</a></li><li><a class="nounderline abstract_t">Viney ME, Brown M, Omoding NE, et al. Why does HIV infection not lead to disseminated strongyloidiasis? J Infect Dis 2004; 190:2175.</a></li><li><a class="nounderline abstract_t">Seet RC, Lau LG, Tambyah PA. Strongyloides hyperinfection and hypogammaglobulinemia. Clin Diagn Lab Immunol 2005; 12:680.</a></li><li><a class="nounderline abstract_t">Sathiyasekaran M, Shibalan S. Intestinal strongyloidiasis and common variable immunodeficiency syndrome. Indian Pediatr 2005; 42:391.</a></li><li><a class="nounderline abstract_t">Adam M, Morgan O, Persaud C, Gibbs WN. Hyperinfection syndrome with Strongyloides stercoralis in malignant lymphoma. Br Med J 1973; 1:264.</a></li><li><a class="nounderline abstract_t">Purtilo DT, Meyers WM, Connor DH. Fatal strongyloidiasis in immunosuppressed patients. Am J Med 1974; 56:488.</a></li><li><a class="nounderline abstract_t">Safdar A, Malathum K, Rodriguez SJ, et al. Strongyloidiasis in patients at a comprehensive cancer center in the United States. Cancer 2004; 100:1531.</a></li><li><a class="nounderline abstract_t">Ghosh K, Ghosh K. Strongyloides stercoralis septicaemia following steroid therapy for eosinophilia: report of three cases. Trans R Soc Trop Med Hyg 2007; 101:1163.</a></li><li><a class="nounderline abstract_t">Boatright MD, Wang BW. Clinical infection with Strongyloides sterocoralis following etanercept use for rheumatoid arthritis. Arthritis Rheum 2005; 52:1336.</a></li><li><a class="nounderline abstract_t">Krishnamurthy R, Dincer HE, Whittemore D. Strongyloides stercoralis hyperinfection in a patient with rheumatoid arthritis after anti-TNF-alpha therapy. J Clin Rheumatol 2007; 13:150.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Transmission of Strongyloides stercoralis through transplantation of solid organs--Pennsylvania, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:264.</a></li><li><a class="nounderline abstract_t">Schaeffer MW, Buell JF, Gupta M, et al. Strongyloides hyperinfection syndrome after heart transplantation: case report and review of the literature. J Heart Lung Transplant 2004; 23:905.</a></li><li><a class="nounderline abstract_t">Lemos LB, Qu Z, Laucirica R, Fred HL. Hyperinfection syndrome in strongyloidiasis: report of two cases. Ann Diagn Pathol 2003; 7:87.</a></li><li><a class="nounderline abstract_t">Hira PR, Al-Ali F, Shweiki HM, et al. Strongyloidiasis: challenges in diagnosis and management in non-endemic Kuwait. Ann Trop Med Parasitol 2004; 98:261.</a></li><li><a class="nounderline abstract_t">Orlent H, Crawley C, Cwynarski K, et al. Strongyloidiasis pre and post autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2003; 32:115.</a></li><li><a class="nounderline abstract_t">Rodríguez-Guardado A, Álvarez-Martínez MJ, Flores MD, et al. Screening for strongyloidiasis in Spain in the context of the SARS-CoV-2 pandemic: Results of a survey on diagnosis and treatment. Enferm Infecc Microbiol Clin (Engl Ed) 2023; 41:329.</a></li><li><a class="nounderline abstract_t">Kim JM, Sivasubramanian G. Strongyloides Hyperinfection Syndrome among COVID-19 Patients Treated with Corticosteroids. Emerg Infect Dis 2022; 28:1531.</a></li><li><a class="nounderline abstract_t">Wikman-Jorgensen P, Requena-Méndez A, Llenas-García J. A Review on Strongyloidiasis in Pregnant Women. Res Rep Trop Med 2021; 12:219.</a></li><li><a class="nounderline abstract_t">Buresch AM, Judge NE, Dayal AK, Garry DJ. A Fatal Case of Strongyloidiasis in Pregnancy. Obstet Gynecol 2015; 126:87.</a></li><li><a class="nounderline abstract_t">Freedman DO. Experimental infection of human subject with Strongyloides species. Rev Infect Dis 1991; 13:1221.</a></li><li><a class="nounderline abstract_t">Khieu V, Srey S, Schär F, et al. Strongyloides stercoralis is a cause of abdominal pain, diarrhea and urticaria in rural Cambodia. BMC Res Notes 2013; 6:200.</a></li><li><a class="nounderline abstract_t">ARTHUR RP, SHELLEY WB. Larva currens; a distinctive variant of cutaneous larva migrans due to Strongyloides stercoralis. AMA Arch Derm 1958; 78:186.</a></li><li><a class="nounderline abstract_t">Tamarozzi F, Martello E, Giorli G, et al. Morbidity Associated with Chronic Strongyloides stercoralis Infection: A Systematic Review and Meta-Analysis. Am J Trop Med Hyg 2019; 100:1305.</a></li><li><a class="nounderline abstract_t">Zubrinich CM, Puy RM, O'Hehir RE, Hew M. Strongyloides infection as a reversible cause of chronic urticaria. J Asthma Allergy 2019; 12:67.</a></li><li><a class="nounderline abstract_t">Rampur L, Jariwala SP, Hudes G, et al. Effect of ivermectin on allergy-type manifestations in occult strongyloidiasis. Ann Allergy Asthma Immunol 2016; 117:423.</a></li><li><a class="nounderline abstract_t">Sen P, Gil C, Estrellas B, Middleton JR. Corticosteroid-induced asthma: a manifestation of limited hyperinfection syndrome due to Strongyloides stercoralis. South Med J 1995; 88:923.</a></li><li><a class="nounderline abstract_t">Salam R, Sharaan A, Jackson SM, et al. Strongyloides Hyperinfection Syndrome: A Curious Case of Asthma Worsened by Systemic Corticosteroids. Am J Case Rep 2020; 21:e925221.</a></li><li><a class="nounderline abstract_t">Wehner JH, Kirsch CM, Kagawa FT, et al. The prevalence and response to therapy of Strongyloides stercoralis in patients with asthma from endemic areas. Chest 1994; 106:762.</a></li><li><a class="nounderline abstract_t">Webster J, Stauffer W, Mitchell T, et al. Cross-Sectional Assessment of the Association of Eosinophilia with Intestinal Parasitic Infection in U.S.-Bound Refugees in Thailand: Prevalent, Age Dependent, but of Limited Clinical Utility. Am J Trop Med Hyg 2022; 106:1552.</a></li><li><a class="nounderline abstract_t">Buonfrate D, Fittipaldo A, Vlieghe E, Bottieau E. Clinical and laboratory features of Strongyloides stercoralis infection at diagnosis and after treatment: a systematic review and meta-analysis. Clin Microbiol Infect 2021; 27:1621.</a></li><li><a class="nounderline abstract_t">Woodring JH, Halfhill H 2nd, Reed JC. Pulmonary strongyloidiasis: clinical and imaging features. AJR Am J Roentgenol 1994; 162:537.</a></li><li><a class="nounderline abstract_t">Salluh JI, Bozza FA, Pinto TS, et al. Cutaneous periumbilical purpura in disseminated strongyloidiasis in cancer patients: a pathognomonic feature of potentially lethal disease? Braz J Infect Dis 2005; 9:419.</a></li><li><a class="nounderline abstract_t">Pivoto João GA, Alves Antunes IF, Mendes Dos Santos L. Fatal Disseminated Strongyloidiasis with Periumbilical Purpura. Am J Trop Med Hyg 2021; 105:860.</a></li><li><a class="nounderline abstract_t">Ghoshal UC, Ghoshal U, Jain M, et al. Strongyloides stercoralis infestation associated with septicemia due to intestinal transmural migration of bacteria. J Gastroenterol Hepatol 2002; 17:1331.</a></li><li><a class="nounderline abstract_t">Natrajan K, Medisetty M, Gawali R, et al. Strongyloidosis Hyperinfection Syndrome in an HIV-Infected Patient: A Rare Manifestation of Immune Reconstitution Inflammatory Syndrome. Case Rep Infect Dis 2018; 2018:6870768.</a></li><li><a class="nounderline abstract_t">Bar-Yoseph H, Zohar Y, Lorber M. Strongyloidiasis-Related IRIS. J Int Assoc Provid AIDS Care 2017; 16:8.</a></li><li><a class="nounderline abstract_t">Mitchell T, Lee D, Weinberg M, et al. Impact of Enhanced Health Interventions for United States-Bound Refugees: Evaluating Best Practices in Migration Health. Am J Trop Med Hyg 2018; 98:920.</a></li><li><a class="nounderline abstract_t">Naidu P, Yanow SK, Kowalewska-Grochowska KT. Eosinophilia: A poor predictor of Strongyloides infection in refugees. Can J Infect Dis Med Microbiol 2013; 24:93.</a></li><li><a class="nounderline abstract_t">Osiro S, Hamula C, Glaser A, et al. A case of Strongyloides hyperinfection syndrome in the setting of persistent eosinophilia but negative serology. Diagn Microbiol Infect Dis 2017; 88:168.</a></li><li><a class="nounderline abstract_t">Geri G, Rabbat A, Mayaux J, et al. Strongyloides stercoralis hyperinfection syndrome: a case series and a review of the literature. Infection 2015; 43:691.</a></li><li><a class="nounderline abstract_t">Requena-Méndez A, Chiodini P, Bisoffi Z, et al. The laboratory diagnosis and follow up of strongyloidiasis: a systematic review. PLoS Negl Trop Dis 2013; 7:e2002.</a></li><li><a class="nounderline abstract_t">Higashiarakawa M, Hirata T, Tanaka T, et al. Normal serum IgE levels and eosinophil counts exhibited during Strongyloides stercoralis infection. Parasitol Int 2017; 66:807.</a></li><li><a class="nounderline abstract_t">Hirata T, Uchima N, Kishimoto K, et al. Impairment of host immune response against strongyloides stercoralis by human T cell lymphotropic virus type 1 infection. Am J Trop Med Hyg 2006; 74:246.</a></li><li><a class="nounderline abstract_t">Porto AF, Neva FA, Bittencourt H, et al. HTLV-1 decreases Th2 type of immune response in patients with strongyloidiasis. Parasite Immunol 2001; 23:503.</a></li><li><a class="nounderline abstract_t">Rivasi F, Pampiglione S, Boldorini R, Cardinale L. Histopathology of gastric and duodenal Strongyloides stercoralis locations in fifteen immunocompromised subjects. Arch Pathol Lab Med 2006; 130:1792.</a></li><li><a class="nounderline abstract_t">Overstreet K, Chen J, Rodriguez JW, Wiener G. Endoscopic and histopathologic findings of Strongyloides stercoralis infection in a patient with AIDS. Gastrointest Endosc 2003; 58:928.</a></li><li><a class="nounderline abstract_t">Aslam A, Barlas U, Yassan LJ, Lodhi M. An unusual case of gastric outlet obstruction and melena. Clin J Gastroenterol 2022; 15:374.</a></li><li><a class="nounderline abstract_t">Pecorella I, Okello TR, Ciardi G, Ogwang DM. Is Gastric Involvement by Strongyloides stercoralis in an Immunocompetent Patient a Common Finding? A Case Report and Review of the Literature. Acta Parasitol 2022; 67:94.</a></li><li><a class="nounderline abstract_t">Qu Z, Kundu UR, Abadeer RA, Wanger A. Strongyloides colitis is a lethal mimic of ulcerative colitis: the key morphologic differential diagnosis. Hum Pathol 2009; 40:572.</a></li><li><a class="nounderline abstract_t">Thompson BF, Fry LC, Wells CD, et al. The spectrum of GI strongyloidiasis: an endoscopic-pathologic study. Gastrointest Endosc 2004; 59:906.</a></li><li><a class="nounderline abstract_t">Agrawal V, Agarwal T, Ghoshal UC. Intestinal strongyloidiasis: a diagnosis frequently missed in the tropics. Trans R Soc Trop Med Hyg 2009; 103:242.</a></li><li><a class="nounderline abstract_t">Al-Hasan MN, McCormick M, Ribes JA. Invasive enteric infections in hospitalized patients with underlying strongyloidiasis. Am J Clin Pathol 2007; 128:622.</a></li><li><a class="nounderline abstract_t">Newberry AM, Williams DN, Stauffer WM, et al. Strongyloides hyperinfection presenting as acute respiratory failure and gram-negative sepsis. Chest 2005; 128:3681.</a></li><li><a class="nounderline abstract_t">Williams J, Nunley D, Dralle W, et al. Diagnosis of pulmonary strongyloidiasis by bronchoalveolar lavage. Chest 1988; 94:643.</a></li><li><a class="nounderline abstract_t">Harris RA Jr, Musher DM, Fainstein V, et al. Disseminated strongyloidiasis. Diagnosis made by sputum examination. JAMA 1980; 244:65.</a></li><li><a class="nounderline abstract_t">Siddiqui AA, Berk SL. Diagnosis of Strongyloides stercoralis infection. Clin Infect Dis 2001; 33:1040.</a></li><li><a class="nounderline abstract_t">Rosenblatt JE. Clinical importance of adequately performed stool ova and parasite examinations. Clin Infect Dis 2006; 42:979.</a></li><li><a class="nounderline abstract_t">Hirata T, Nakamura H, Kinjo N, et al. Increased detection rate of Strongyloides stercoralis by repeated stool examinations using the agar plate culture method. Am J Trop Med Hyg 2007; 77:683.</a></li><li><a class="nounderline abstract_t">Ketzis JK. Limitations to the adoption of a standardized Strongyloides stercoralis diagnostic method: Case study in the Caribbean. Acta Trop 2017; 170:178.</a></li><li><a class="nounderline abstract_t">Buonfrate D, Perandin F, Formenti F, Bisoffi Z. A retrospective study comparing agar plate culture, indirect immunofluorescence and real-time PCR for the diagnosis of Strongyloides stercoralis infection. Parasitology 2017; 144:812.</a></li><li><a class="nounderline abstract_t">Buonfrate D, Formenti F, Perandin F, Bisoffi Z. Novel approaches to the diagnosis of Strongyloides stercoralis infection. Clin Microbiol Infect 2015; 21:543.</a></li><li><a class="nounderline abstract_t">Campo Polanco L, Gutiérrez LA, Cardona Arias J. [Diagnosis of Strongyloides Stercoralis infection: meta-analysis on evaluation of conventional parasitological methods (1980-2013)]. Rev Esp Salud Publica 2014; 88:581.</a></li><li><a class="nounderline abstract_t">Ramanathan R, Nutman T. Strongyloides stercoralis infection in the immunocompromised host. Curr Infect Dis Rep 2008; 10:105.</a></li><li class="breakAll">https://www.cdc.gov/dpdx/contact.html (Accessed on September 10, 2019).</li><li><a class="nounderline abstract_t">Greiner K, Bettencourt J, Semolic C. Strongyloidiasis: a review and update by case example. Clin Lab Sci 2008; 21:82.</a></li><li><a class="nounderline abstract_t">Dreyer G, Fernandes-Silva E, Alves S, et al. Patterns of detection of Strongyloides stercoralis in stool specimens: implications for diagnosis and clinical trials. J Clin Microbiol 1996; 34:2569.</a></li><li><a class="nounderline abstract_t">Sharifdini M, Mirhendi H, Ashrafi K, et al. Comparison of Nested Polymerase Chain Reaction and Real-Time Polymerase Chain Reaction with Parasitological Methods for Detection of Strongyloides stercoralis in Human Fecal Samples. Am J Trop Med Hyg 2015; 93:1285.</a></li><li><a class="nounderline abstract_t">Repetto SA, Alba Soto CD, Cazorla SI, et al. An improved DNA isolation technique for PCR detection of Strongyloides stercoralis in stool samples. Acta Trop 2013; 126:110.</a></li><li><a class="nounderline abstract_t">Barda B, Wampfler R, Sayasone S, et al. Evaluation of Two DNA Extraction Methods for Detection of Strongyloides stercoralis Infection. J Clin Microbiol 2018; 56.</a></li><li><a class="nounderline abstract_t">Buonfrate D, Requena-Mendez A, Angheben A, et al. Accuracy of molecular biology techniques for the diagnosis of Strongyloides stercoralis infection-A systematic review and meta-analysis. PLoS Negl Trop Dis 2018; 12:e0006229.</a></li><li><a class="nounderline abstract_t">Repetto SA, Ruybal P, Solana ME, et al. Comparison between PCR and larvae visualization methods for diagnosis of Strongyloides stercoralis out of endemic area: A proposed algorithm. Acta Trop 2016; 157:169.</a></li><li><a class="nounderline abstract_t">Carroll SM, Karthigasu KT, Grove DI. Serodiagnosis of human strongyloidiasis by an enzyme-linked immunosorbent assay. Trans R Soc Trop Med Hyg 1981; 75:706.</a></li><li><a class="nounderline abstract_t">Abdalla J, Saad M, Myers JW, Moorman JP. An elderly man with immunosuppression, shortness of breath, and eosinophilia. Clin Infect Dis 2005; 40:1464, 1535.</a></li><li><a class="nounderline abstract_t">Ming DK, Armstrong M, Lowe P, et al. Clinical and Diagnostic Features of 413 Patients Treated for Imported Strongyloidiasis at the Hospital for Tropical Diseases, London. Am J Trop Med Hyg 2019; 101:428.</a></li><li><a class="nounderline abstract_t">Sudarshi S, Stümpfle R, Armstrong M, et al. Clinical presentation and diagnostic sensitivity of laboratory tests for Strongyloides stercoralis in travellers compared with immigrants in a non-endemic country. Trop Med Int Health 2003; 8:728.</a></li><li><a class="nounderline abstract_t">van Doorn HR, Koelewijn R, Hofwegen H, et al. Use of enzyme-linked immunosorbent assay and dipstick assay for detection of Strongyloides stercoralis infection in humans. J Clin Microbiol 2007; 45:438.</a></li><li><a class="nounderline abstract_t">Anderson NW, Klein DM, Dornink SM, et al. Comparison of three immunoassays for detection of antibodies to Strongyloides stercoralis. Clin Vaccine Immunol 2014; 21:732.</a></li><li><a class="nounderline abstract_t">Balachandra D, Ahmad H, Arifin N, Noordin R. Direct detection of Strongyloides infection via molecular and antigen detection methods. Eur J Clin Microbiol Infect Dis 2021; 40:27.</a></li><li><a class="nounderline abstract_t">Tamarozzi F, Longoni SS, Mazzi C, et al. The accuracy of a recombinant antigen immunochromatographic test for the detection of Strongyloides stercoralis infection in migrants from sub-Saharan Africa. Parasit Vectors 2022; 15:142.</a></li><li><a class="nounderline abstract_t">Ruantip S, Eamudomkarn C, Kopolrat KY, et al. Analysis of Daily Variation for 3 and for 30 Days of Parasite-Specific IgG in Urine for Diagnosis of Strongyloidiasis by Enzyme-Linked Immunosorbent Assay. Acta Trop 2021; 218:105896.</a></li><li><a class="nounderline abstract_t">Eamudomkarn C, Sithithaworn P, Kamamia C, et al. Diagnostic performance of urinary IgG antibody detection: A novel approach for population screening of strongyloidiasis. PLoS One 2018; 13:e0192598.</a></li><li><a class="nounderline abstract_t">Chungkanchana N, Sithithaworn P, Worasith C, et al. Concentration of Urine Samples Improves Sensitivity in Detection of Strongyloides-Specific IgG Antibody in Urine for Diagnosis of Strongyloidiasis. J Clin Microbiol 2022; 60:e0145421.</a></li><li><a class="nounderline abstract_t">Henriquez-Camacho C, Gotuzzo E, Echevarria J, et al. Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection. Cochrane Database Syst Rev 2016; :CD007745.</a></li><li><a class="nounderline abstract_t">Repetto SA, Ruybal P, Batalla E, et al. Strongyloidiasis Outside Endemic Areas: Long-term Parasitological and Clinical Follow-up After Ivermectin Treatment. Clin Infect Dis 2018; 66:1558.</a></li><li><a class="nounderline abstract_t">Schulz JD, Coulibaly JT, Schindler C, et al. Pharmacokinetics of ascending doses of ivermectin in Trichuris trichiura-infected children aged 2-12 years. J Antimicrob Chemother 2019; 74:1642.</a></li><li><a class="nounderline abstract_t">Duthaler U, Suenderhauf C, Karlsson MO, et al. Population pharmacokinetics of oral ivermectin in venous plasma and dried blood spots in healthy volunteers. Br J Clin Pharmacol 2019; 85:626.</a></li><li><a class="nounderline abstract_t">Muñoz J, Ballester MR, Antonijoan RM, et al. Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers. PLoS Negl Trop Dis 2018; 12:e0006020.</a></li><li><a class="nounderline abstract_t">Suputtamongkol Y, Premasathian N, Bhumimuang K, et al. Efficacy and safety of single and double doses of ivermectin versus 7-day high dose albendazole for chronic strongyloidiasis. PLoS Negl Trop Dis 2011; 5:e1044.</a></li><li><a class="nounderline abstract_t">Gann PH, Neva FA, Gam AA. A randomized trial of single- and two-dose ivermectin versus thiabendazole for treatment of strongyloidiasis. J Infect Dis 1994; 169:1076.</a></li><li class="breakAll">Drugs for Parasitic Infections, 3rd ed, The Medical Letter, New Rochelle, NY 2013.</li><li><a class="nounderline abstract_t">Zaha O, Hirata T, Kinjo F, et al. Efficacy of ivermectin for chronic strongyloidiasis: two single doses given 2 weeks apart. J Infect Chemother 2002; 8:94.</a></li><li><a class="nounderline abstract_t">Greaves D, Coggle S, Pollard C, et al. Strongyloides stercoralis infection. BMJ 2013; 347:f4610.</a></li><li><a class="nounderline abstract_t">Buonfrate D, Salas-Coronas J, Muñoz J, et al. Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial. Lancet Infect Dis 2019; 19:1181.</a></li><li><a class="nounderline abstract_t">Pornsuriyasak P, Niticharoenpong K, Sakapibunnan A. Disseminated strongyloidiasis successfully treated with extended duration ivermectin combined with albendazole: a case report of intractable strongyloidiasis. Southeast Asian J Trop Med Public Health 2004; 35:531.</a></li><li><a class="nounderline abstract_t">Segarra-Newnham M. Manifestations, diagnosis, and treatment of Strongyloides stercoralis infection. Ann Pharmacother 2007; 41:1992.</a></li><li><a class="nounderline abstract_t">Marty FM, Lowry CM, Rodriguez M, et al. Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin. Clin Infect Dis 2005; 41:e5.</a></li><li><a class="nounderline abstract_t">Barrett J, Broderick C, Soulsby H, et al. Subcutaneous ivermectin use in the treatment of severe Strongyloides stercoralis infection: two case reports and a discussion of the literature. J Antimicrob Chemother 2016; 71:220.</a></li><li><a class="nounderline abstract_t">Tarr PE, Miele PS, Peregoy KS, et al. Case report: Rectal adminstration of ivermectin to a patient with Strongyloides hyperinfection syndrome. Am J Trop Med Hyg 2003; 68:453.</a></li><li><a class="nounderline abstract_t">Bogoch II, Khan K, Abrams H, et al. Failure of ivermectin per rectum to achieve clinically meaningful serum levels in two cases of Strongyloides hyperinfection. Am J Trop Med Hyg 2015; 93:94.</a></li><li><a class="nounderline abstract_t">Nuesch R, Zimmerli L, Stockli R, et al. Imported strongyloidosis: a longitudinal analysis of 31 cases. J Travel Med 2005; 12:80.</a></li><li><a class="nounderline abstract_t">Igual-Adell R, Oltra-Alcaraz C, Soler-Company E, et al. Efficacy and safety of ivermectin and thiabendazole in the treatment of strongyloidiasis. Expert Opin Pharmacother 2004; 5:2615.</a></li><li><a class="nounderline abstract_t">Biggs BA, Caruana S, Mihrshahi S, et al. Management of chronic strongyloidiasis in immigrants and refugees: is serologic testing useful? Am J Trop Med Hyg 2009; 80:788.</a></li><li><a class="nounderline abstract_t">Salvador F, Sulleiro E, Sánchez-Montalvá A, et al. Usefulness of Strongyloides stercoralis serology in the management of patients with eosinophilia. Am J Trop Med Hyg 2014; 90:830.</a></li><li><a class="nounderline abstract_t">Terashima A, Alvarez H, Tello R, et al. Treatment failure in intestinal strongyloidiasis: an indicator of HTLV-I infection. Int J Infect Dis 2002; 6:28.</a></li><li><a class="nounderline abstract_t">Jeyamani R, Joseph AJ, Chacko A. Severe and treatment resistant strongyloidiasis--indicator of HTLV-I infection. Trop Gastroenterol 2007; 28:176.</a></li><li><a class="nounderline abstract_t">Lam CS, Tong MK, Chan KM, Siu YP. Disseminated strongyloidiasis: a retrospective study of clinical course and outcome. Eur J Clin Microbiol Infect Dis 2006; 25:14.</a></li><li><a class="nounderline abstract_t">El Masry HZ, O'Donnell J. Fatal stongyloides hyperinfection in heart transplantation. J Heart Lung Transplant 2005; 24:1980.</a></li><li><a class="nounderline abstract_t">Mejia R, Nutman TB. Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by Strongyloides stercoralis. Curr Opin Infect Dis 2012; 25:458.</a></li><li><a class="nounderline abstract_t">Roxby AC, Gottlieb GS, Limaye AP. Strongyloidiasis in transplant patients. Clin Infect Dis 2009; 49:1411.</a></li><li><a class="nounderline abstract_t">Paula FM, Malta FM, Marques PD, et al. Molecular diagnosis of Strongyloides stercoralis among transplant candidates. Transpl Infect Dis 2018; 20:e12909.</a></li><li><a class="nounderline abstract_t">Gill GV, Welch E, Bailey JW, et al. Chronic Strongyloides stercoralis infection in former British Far East prisoners of war. QJM 2004; 97:789.</a></li><li><a class="nounderline abstract_t">Johnston FH, Morris PS, Speare R, et al. Strongyloidiasis: a review of the evidence for Australian practitioners. Aust J Rural Health 2005; 13:247.</a></li><li><a class="nounderline abstract_t">Lim S, Katz K, Krajden S, et al. Complicated and fatal Strongyloides infection in Canadians: risk factors, diagnosis and management. CMAJ 2004; 171:479.</a></li><li><a class="nounderline abstract_t">Eperon G, Tourret J, Ailioaie O, et al. Severe Strongyloidiasis in Solid Organ Transplant Recipients: Should We Preventively Treat the Recipient, the Donor, or Both? Am J Trop Med Hyg 2018; 98:941.</a></li></ol></div><div id="topicVersionRevision">Topic 5714 Version 46.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35857754" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Seroprevalence of Strongyloides stercoralis infection in a South Indian adult population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35396957" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Strongyloides stercoralis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32545787" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The Global Prevalence of Strongyloides stercoralis Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30712758" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Strongyloidiasis: A Neglected Tropical Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28882382" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Soil-transmitted helminth infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28749768" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Evidence-Based Guidelines for Screening and Management of Strongyloidiasis in Non-Endemic Countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31145496" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Intestinal parasites including Cryptosporidium, Cyclospora, Giardia, and Microsporidia, Entamoeba histolytica, Strongyloides, Schistosomiasis, and Echinococcus: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23875033" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Strongyloides stercoralis: Global Distribution and Risk Factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34520539" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Is strongyloidiasis currently autochthonous in Croatia? A retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33898349" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The autochthonous cases of acute strongyloidiasis in the Moscow region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32503315" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Autochthonous Human and Canine Strongyloides stercoralis Infection in Europe: Report of a Human Case in An Italian Teen and Systematic Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24153316" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Notes from the field: Strongyloidiasis in a rural setting--Southeastern Kentucky, 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24153317" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Notes from the field: strongyloides infection among patients at a long-term care facility--Florida, 2010-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34287125" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Parasitic Disease Surveillance, Mississippi, USA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35313336" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Hospitalizations Associated With Strongyloidiasis in the United States, 2003-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17968826" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : High prevalence and presumptive treatment of schistosomiasis and strongyloidiasis among African refugees.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2196791" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Seroepidemiology of Strongyloides infection in the Southeast Asian refugee population in Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33480433" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Helminth infections in the US military: from strongyloidiasis to schistosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30683241" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Prevalence of strongyloidiasis and schistosomiasis among migrants: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31758828" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Strongyloidiasis screening in migrants living in Spain: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35184771" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Global prevalence of Strongyloides stercoralis in dogs: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28793306" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Different but overlapping populations of Strongyloides stercoralis in dogs and humans-Dogs as a possible source for zoonotic strongyloidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32860989" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Possible transmission of Strongyloides fuelleborni between working Southern pig-tailed macaques (Macaca nemestrina) and their owners in Southern Thailand: Molecular identification and diversity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28366929" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Strongyloides Stercoralis Infection Among Human Immunodeficiency Virus (HIV)-Infected Patients in the United States of America: A Case Report and Review of Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27310213" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Notes from the Field: Strongyloidiasis at a Long-Term-Care Facility for the Developmentally Disabled - Arizona, 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16944262" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Exposure of medical staff to Strongyloides stercolaris from a patient with disseminated strongyloidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25703251" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Donor-derived Strongyloides stercoralis infection in solid organ transplant recipients in the United States, 2009-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35987856" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A comprehensive review of Strongyloides stercoralis infection after solid organ and hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2347234" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pulmonary hyperinfection syndrome with Strongyloides stercoralis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3343527" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Diagnosis and evaluation of treatment of chronic strongyloidiasis in ex-prisoners of war.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14726461" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Strongyloides stercoralis in the Immunocompromised Population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8058699" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pathogenesis of human strongyloidiasis: autopsy and quantitative parasitological analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35237633" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Human T-Cell Lymphotropic Virus Type 1 and Strongyloides stercoralis Co-infection: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7934810" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Systemic strongyloidiasis in patients infected with the human immunodeficiency virus. A report of 3 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8325052" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Disseminated Strongyloides stercoralis in human immunodeficiency virus-infected patients. Treatment failure and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15551217" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Why does HIV infection not lead to disseminated strongyloidiasis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15879034" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Strongyloides hyperinfection and hypogammaglobulinemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15876606" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Intestinal strongyloidiasis and common variable immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4685318" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Hyperinfection syndrome with Strongyloides stercoralis in malignant lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4818417" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Fatal strongyloidiasis in immunosuppressed patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15042689" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Strongyloidiasis in patients at a comprehensive cancer center in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17662320" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Strongyloides stercoralis septicaemia following steroid therapy for eosinophilia: report of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15818680" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Clinical infection with Strongyloides sterocoralis following etanercept use for rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17551383" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Strongyloides stercoralis hyperinfection in a patient with rheumatoid arthritis after anti-TNF-alpha therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23575239" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Transmission of Strongyloides stercoralis through transplantation of solid organs--Pennsylvania, 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15261189" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Strongyloides hyperinfection syndrome after heart transplantation: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12715333" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Hyperinfection syndrome in strongyloidiasis: report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15119971" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Strongyloidiasis: challenges in diagnosis and management in non-endemic Kuwait.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12815488" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Strongyloidiasis pre and post autologous peripheral blood stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35970704" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Screening for strongyloidiasis in Spain in the context of the SARS-CoV-2 pandemic: Results of a survey on diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35731220" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Strongyloides Hyperinfection Syndrome among COVID-19 Patients Treated with Corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34584485" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A Review on Strongyloidiasis in Pregnant Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25774935" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A Fatal Case of Strongyloidiasis in Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1775856" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Experimental infection of human subject with Strongyloides species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23688049" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Strongyloides stercoralis is a cause of abdominal pain, diarrhea and urticaria in rural Cambodia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13558704" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Larva currens; a distinctive variant of cutaneous larva migrans due to Strongyloides stercoralis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30963990" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Morbidity Associated with Chronic Strongyloides stercoralis Infection: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30881049" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Strongyloides infection as a reversible cause of chronic urticaria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27566864" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Effect of ivermectin on allergy-type manifestations in occult strongyloidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7660209" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Corticosteroid-induced asthma: a manifestation of limited hyperinfection syndrome due to Strongyloides stercoralis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33347427" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Strongyloides Hyperinfection Syndrome: A Curious Case of Asthma Worsened by Systemic Corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8082356" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The prevalence and response to therapy of Strongyloides stercoralis in patients with asthma from endemic areas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35483390" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Cross-Sectional Assessment of the Association of Eosinophilia with Intestinal Parasitic Infection in U.S.-Bound Refugees in Thailand: Prevalent, Age Dependent, but of Limited Clinical Utility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34325063" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Clinical and laboratory features of Strongyloides stercoralis infection at diagnosis and after treatment: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8109492" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Pulmonary strongyloidiasis: clinical and imaging features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16410894" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Cutaneous periumbilical purpura in disseminated strongyloidiasis in cancer patients: a pathognomonic feature of potentially lethal disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34181569" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Fatal Disseminated Strongyloidiasis with Periumbilical Purpura.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12423282" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Strongyloides stercoralis infestation associated with septicemia due to intestinal transmural migration of bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30510823" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Strongyloidosis Hyperinfection Syndrome in an HIV-Infected Patient: A Rare Manifestation of Immune Reconstitution Inflammatory Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27733639" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Strongyloidiasis-Related IRIS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29260657" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Impact of Enhanced Health Interventions for United States-Bound Refugees: Evaluating Best Practices in Migration Health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24421809" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Eosinophilia: A poor predictor of Strongyloides infection in refugees.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28377165" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : A case of Strongyloides hyperinfection syndrome in the setting of persistent eosinophilia but negative serology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26008854" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Strongyloides stercoralis hyperinfection syndrome: a case series and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23350004" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The laboratory diagnosis and follow up of strongyloidiasis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27744050" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Normal serum IgE levels and eosinophil counts exhibited during Strongyloides stercoralis infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16474078" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Impairment of host immune response against strongyloides stercoralis by human T cell lymphotropic virus type 1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11589779" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : HTLV-1 decreases Th2 type of immune response in patients with strongyloidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17149952" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Histopathology of gastric and duodenal Strongyloides stercoralis locations in fifteen immunocompromised subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14652568" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Endoscopic and histopathologic findings of Strongyloides stercoralis infection in a patient with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35064555" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : An unusual case of gastric outlet obstruction and melena.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34143401" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Is Gastric Involvement by Strongyloides stercoralis in an Immunocompetent Patient a Common Finding? A Case Report and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19144377" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Strongyloides colitis is a lethal mimic of ulcerative colitis: the key morphologic differential diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15173813" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The spectrum of GI strongyloidiasis: an endoscopic-pathologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18804829" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Intestinal strongyloidiasis: a diagnosis frequently missed in the tropics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17875514" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Invasive enteric infections in hospitalized patients with underlying strongyloidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16304332" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Strongyloides hyperinfection presenting as acute respiratory failure and gram-negative sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3409752" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Diagnosis of pulmonary strongyloidiasis by bronchoalveolar lavage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7382060" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Disseminated strongyloidiasis. Diagnosis made by sputum examination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11528578" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Diagnosis of Strongyloides stercoralis infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16511763" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Clinical importance of adequately performed stool ova and parasite examinations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17978071" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Increased detection rate of Strongyloides stercoralis by repeated stool examinations using the agar plate culture method.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28279703" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Limitations to the adoption of a standardized Strongyloides stercoralis diagnostic method: Case study in the Caribbean.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28073382" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : A retrospective study comparing agar plate culture, indirect immunofluorescence and real-time PCR for the diagnosis of Strongyloides stercoralis infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25887711" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Novel approaches to the diagnosis of Strongyloides stercoralis infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25327268" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : [Diagnosis of Strongyloides Stercoralis infection: meta-analysis on evaluation of conventional parasitological methods (1980-2013)].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18462583" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Strongyloides stercoralis infection in the immunocompromised host.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18462583" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Strongyloides stercoralis infection in the immunocompromised host.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18507302" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Strongyloidiasis: a review and update by case example.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8880521" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Patterns of detection of Strongyloides stercoralis in stool specimens: implications for diagnosis and clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26350449" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Comparison of Nested Polymerase Chain Reaction and Real-Time Polymerase Chain Reaction with Parasitological Methods for Detection of Strongyloides stercoralis in Human Fecal Samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23416126" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : An improved DNA isolation technique for PCR detection of Strongyloides stercoralis in stool samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29367294" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Evaluation of Two DNA Extraction Methods for Detection of Strongyloides stercoralis Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29425193" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Accuracy of molecular biology techniques for the diagnosis of Strongyloides stercoralis infection-A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26868702" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Comparison between PCR and larvae visualization methods for diagnosis of Strongyloides stercoralis out of endemic area: A proposed algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7036430" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Serodiagnosis of human strongyloidiasis by an enzyme-linked immunosorbent assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15846856" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : An elderly man with immunosuppression, shortness of breath, and eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31219002" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Clinical and Diagnostic Features of 413 Patients Treated for Imported Strongyloidiasis at the Hospital for Tropical Diseases, London.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12869094" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Clinical presentation and diagnostic sensitivity of laboratory tests for Strongyloides stercoralis in travellers compared with immigrants in a non-endemic country.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17151215" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Use of enzyme-linked immunosorbent assay and dipstick assay for detection of Strongyloides stercoralis infection in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24648484" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Comparison of three immunoassays for detection of antibodies to Strongyloides stercoralis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32729057" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Direct detection of Strongyloides infection via molecular and antigen detection methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35461265" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : The accuracy of a recombinant antigen immunochromatographic test for the detection of Strongyloides stercoralis infection in migrants from sub-Saharan Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33753029" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Analysis of Daily Variation for 3 and for 30 Days of Parasite-Specific IgG in Urine for Diagnosis of Strongyloidiasis by Enzyme-Linked Immunosorbent Assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29985913" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Diagnostic performance of urinary IgG antibody detection: A novel approach for population screening of strongyloidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34705534" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Concentration of Urine Samples Improves Sensitivity in Detection of Strongyloides-Specific IgG Antibody in Urine for Diagnosis of Strongyloidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26778150" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29360939" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Strongyloidiasis Outside Endemic Areas: Long-term Parasitological and Clinical Follow-up After Ivermectin Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30859185" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Pharmacokinetics of ascending doses of ivermectin in Trichuris trichiura-infected children aged 2-12 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30566757" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Population pharmacokinetics of oral ivermectin in venous plasma and dried blood spots in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29346388" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21572981" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Efficacy and safety of single and double doses of ivermectin versus 7-day high dose albendazole for chronic strongyloidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8169394" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : A randomized trial of single- and two-dose ivermectin versus thiabendazole for treatment of strongyloidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8169394" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : A randomized trial of single- and two-dose ivermectin versus thiabendazole for treatment of strongyloidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11957127" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Efficacy of ivermectin for chronic strongyloidiasis: two single doses given 2 weeks apart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23900531" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Strongyloides stercoralis infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31558376" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15689061" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Disseminated strongyloidiasis successfully treated with extended duration ivermectin combined with albendazole: a case report of intractable strongyloidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17940124" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Manifestations, diagnosis, and treatment of Strongyloides stercoralis infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15937753" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26462990" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Subcutaneous ivermectin use in the treatment of severe Strongyloides stercoralis infection: two case reports and a discussion of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12875295" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Case report: Rectal adminstration of ivermectin to a patient with Strongyloides hyperinfection syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25918215" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Failure of ivermectin per rectum to achieve clinically meaningful serum levels in two cases of Strongyloides hyperinfection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15996452" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Imported strongyloidosis: a longitudinal analysis of 31 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15571478" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Efficacy and safety of ivermectin and thiabendazole in the treatment of strongyloidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19407125" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Management of chronic strongyloidiasis in immigrants and refugees: is serologic testing useful?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24615124" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Usefulness of Strongyloides stercoralis serology in the management of patients with eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12044298" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Treatment failure in intestinal strongyloidiasis: an indicator of HTLV-I infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18416349" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Severe and treatment resistant strongyloidiasis--indicator of HTLV-I infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16418832" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Disseminated strongyloidiasis: a retrospective study of clinical course and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16297809" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Fatal stongyloides hyperinfection in heart transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22691685" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by Strongyloides stercoralis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19807271" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Strongyloidiasis in transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29679429" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Molecular diagnosis of Strongyloides stercoralis among transplant candidates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15569810" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Chronic Strongyloides stercoralis infection in former British Far East prisoners of war.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16048468" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Strongyloidiasis: a review of the evidence for Australian practitioners.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15337730" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Complicated and fatal Strongyloides infection in Canadians: risk factors, diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29363441" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Severe Strongyloidiasis in Solid Organ Transplant Recipients: Should We Preventively Treat the Recipient, the Donor, or Both?</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
